Keep pulling the thread on Dr. Sudhir Srivastava.
Johnson & Johnson has launched a robot for soft tissue surgery.
Growth in the use of Intuitive Surgical's da Vinci surgical robot has slowed to the weakest pace in four years.
U.S. bariatric procedures using Intuitive Surgical's da Vinci robot are facing pressure from patient adoption of GLP-1 weight loss drugs.
SS Innovations anticipates receiving regulatory approval from the US FDA for its surgical robot by the first quarter of 2025.
SS Innovations plans to price its Mantra surgical system at less than half the price of the Intuitive Surgical da Vinci 5 upon entering the U.S. market.
Investor sentiment for SS Innovations is primarily contingent on the company securing U.S. FDA approval and generating U.S. revenues.
Dr. Fred Moll, a founder of Intuitive Surgical, serves as the Vice Chair of SS Innovations.
SS Innovations has been evaluated by potential acquirers under non-disclosure agreements.
Intuitive Surgical's guidance for procedure growth was unchanged due to softer U.S. growth caused by changes to Affordable Care Act subsidies.
SS Innovations International has a market capitalization of $683 million.
Shares of SS Innovations International have declined approximately 40% year-to-date.
The SSI Mantra surgical robot features an open-face console with a 32-inch 4K monitor and can control up to five arms, contrasting with the immersive design of the da Vinci system.